|Bid||2.2800 x 21500|
|Ask||2.2900 x 1000|
|Day's range||2.0800 - 2.3650|
|52-week range||1.1200 - 2.9100|
|Beta (5Y monthly)||2.27|
|PE ratio (TTM)||N/A|
|Earnings date||05 Aug 2020 - 10 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.15|
MIAMI, May 27, 2020 -- OPKO Health, Inc. (NASDAQ: OPK) announced today that management will be participating in the Jefferies Virtual Healthcare Conference being held June.
OPKO Health, Inc. (OPK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
OPKO Health's (OPK) subsidiary, BioReference Laboratories collaborates with MagnaCare to offer antibody testing to Labor groups in New York metropolitan area.
After announcing it has launched a COVID-19 screening program to help employers make return-to-work decisions for employees, OPKO Health (NASDAQ: OPK) saw its shares close the day up more than 10% on Thursday. OPKO Health's BioReference Labs has been assisting healthcare providers with COVID-19 testing services since mid-March. On Monday, management expanded its COVID-19 product platform with the launch of an antibody test that can determine if someone has been exposed to the virus, and on Wednesday, the healthcare company unveiled services designed to inform business decisions relating to employees.
Its BioReference subsidiary is rolling out testing with five locations -- one in each of NYC's boroughs -- but will quickly expand its footprint.
What happened After reporting a year-over-year decline in revenue that was worse than industry watchers expected, OPKO Health (NASDAQ: OPK) saw its shares fall 16.7% on Thursday. So what Although the healthcare company is benefiting from significant demand for COVID-19 tests, rising demand in the final weeks of the first quarter wasn't enough to offset declining demand for lab services caused by widespread shelter-in-place orders that reduced visits to primary- and specialty-care doctors.
OPKO Health (NASDAQ: OPK) lost more than half its value last year, but so far in 2020, the stock has soared more than 40%. Here are the highlights from OPKO's Q1 update. The good news is that OPKO's bottom line moved in a positive direction.
MIAMI, May 06, 2020 -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2020. Business Highlights.
MIAMI, April 30, 2020 -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2020, as well as discuss financial.
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OPKO Health, Inc. (NASDAQ: OPK) today provided an update on two abstracts regarding the global Phase 3 somatrogon pediatric trial evaluating somatrogon dosed once weekly in pre-pubertal children with growth hormone deficiency (GHD). The data from the two abstracts, which were previously accepted for oral presentation at the Endocrine Society’s (ENDO) 2020 meeting, will now be combined into a single presentation at ENDO Online 2020, a virtual event being held June 8 through 22 that will feature on-demand and live programming. The virtual event will incorporate select content from the ENDO 2020 meeting previously scheduled for March 29 through 30 in San Francisco, which was cancelled due to the COVID-19 outbreak.
Phase 4 Head-to-Head Study in Patients with Stage 3 or 4 Chronic Kidney Disease Phase 2 Trial in Patients with Stage 5 Chronic Kidney Disease on Dialysis MIAMI, March 25, 2020.
The Zacks Analyst Blog Highlights: Co-Diagnostics, GenMark Diagnostics, OPKO Health and Inovio Pharmaceuticals
Pomerantz LLP is investigating claims on behalf of investors of OPKO Health, Inc. (“OPKO” or the “Company”) (NASDAQ: OPK). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether OPKO and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.